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Role of a rat membrane inhibitor of complement in anti-basement
membrane antibody-induced renal injury. In the kidneys of anti-glomer-
ular basement membrane (anti-GBM) antibody disease, binding of anti-
bodies to tubular basement membrane (TBM) is often observed. The
present work was performed to explore the mechanisms of binding of
anti-GBM antibodies to TBM in vivo with special reference to 5I2Ag, a rat
membrane inhibitor of complement which regulates complement activa-
tion at C3 convertase level. To suppress functions of renal 5I2Ag, F(ab')2
fragment of 512 (a neutralizing mAb against 5I2Ag) was perfused in the
left kidney and then blood circulation was restored. Mild proteinuria
(< 10 mgIl6 hr) was observed during first several days. Five days later,
there were tubulointerstitial injuries defined by tubular vimentin staining
and leukocyte infiltration. Significant deposition of C3 was observed in the
capillaries and in TBM. In rats intravenously injected with rabbit anti-rat
GBM antibodies five minutes after kidney perfusion with 512, strong
binding of rabbit IgG to TBM was observed at one and five days after
injection. Although these rats showed mild proteinuria comparable to
those perfused with 512 and those injected with normal rabbit serum,
tubulointerstitial injury was significantly enhanced at Day 5. In contrast,
rats perfused with irrelevant mAb and injected with anti-GBM antibodies
did not show any significant binding of antibodies to TBM nor tubuloin-
terstitiat injury. Furthermore, rats which were made proteinuric by
puromycin aminonucleoside and injected with anti-GBM antibodies did
not show any significant binding of rabbit IgG to TBM. These results
indicate that 5I2Ag, a rat membrane inhibitor of complement at the C3
convertase level, regulates vascular permeability in the living kidney, and
that dysfunction or decreased expression of this molecule leads to
increased accessibility of anti-GBM antibodies to TBM.
In human anti-GBM nephritis, more than 60% of patients were
reported to have antibody deposition along tubular basement
membrane (TBM), and those who had antibody deposition along
the TBM showed a higher degree of tubulointerstitial injury [1]. In
experimental anti-GBM nephritis in rats, weak binding of anti-
GBM antibodies along the TBM of occasional proximal tubules
was reported, and there was mononuclear cell infiltration in these
area. Eddy and coworkers proposed that the mechanism of
antibody deposition along the TBM was due to absorption of
anti-GBM antibodies leaked from glomeruli to tubular lumen,
because the increase of glomerular permeability by puromycin
aminonucleoside enhanced the antibody deposition along TBM
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[2]. However, the second possibility that antibodies reach the
TBM directly through vasculatures cannot be excluded. It might
be hypothesized that an increase of vascular permeability can
make anti-GBM antibodies accessible to TBM.
A family of glycoprotein molecules, cell membrane-associated
complement regulatory proteins or membrane inhibitors of com-
plement, are present on the plasma membranes of a wide variety
of host cells, and inhibit complement activation on the host cell
membranes at levels of C3 amplification loop and formation of
membrane attack complex (MAC) [3]. In vivo studies to assess the
roles of these molecules have only recently begun using a rat
system, and it is now considered that these molecules play crucial
roles in the host cell defense against autologous complement
attack both in the normal and diseased conditions. In our recent
study, in vivo suppression of a rat complement regulatory protein
5I2Ag [4, 5], an antigen recognized by a mouse mAb (mAb) 512,
or a rat counterpart of mouse CrryIp65 [6—8]] rendered rats
susceptible to autologous complement attack and induced endo-
toxin shock-like symptoms in rats [9]. In these rats, vascular
permeability was highly increased [9].
Suppression of renal 5I2Ag by a mAb greatly increased the
accessibility of heterologous anti-GBM antibodies to TBM. Thus,
this work was designed to clarify the role of a rat complement
regulatory protein 5I2Ag in the experimental anti-GBM nephritis
in rats. The results obtained in this study might have relevance to
understanding tubulointerstitial injury in anti-GBM nephritis in
humans.
Methods
Animals
Female Wistar rats weighing about 300 grams and Japanese
white rabbits weighing about 2.5 kg were purchased from Chubu
Kagaku Shizai Co. Ltd. (Nagoya, Japan). They were allowed free
access to food and water throughout the experiments.
Antibodies
Heterologous anti-rat GBM sera were produced in rabbits
according to a method described before [10]. Rabbits were
immunized subcutaneously with GBM in complete Freund's
adjuvant every two weeks and were bled 32 days after the first
immunization. Complements were inactivated by incubating anti-
sera at 56°C for 30 minutes. Antisera were then absorbed with
normal rat liver powder and erythrocytes. These antisera (rabbit
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anti-GBM sera) showed binding to GBM, TBM and basement
membranes of all vessels when tested on normal rat kidney
sections by indirect immunofluorescence technique (indirect IF).
As described in a previous paper [101, intravenous injection of 1.0
ml of this antisera induced a very mild cellular infiltration in the
glomeruli and did not induce significant proteinuria during the
heterologous phase.
Characteristics and properties of mAb 512 (IgGi subclass) have
been described [4]. The mAb 512 can inhibit the function of a cell
membrane-associated rat complement regulatory protein 5I2Ag
(a rat counterpart of mouse Crry/p65) which regulates C3 con-
vertases of both classical and alternative pathways. F(ab')2 frag-
ments of 512 were prepared according to a method described
previously [9]. H38 is an irrelevant mAb of IgGi subclass which
does not react with rat tissues. F(ab')2 fragments were also
prepared and used as a control antibody for 512.
Kidney perfusion
To inhibit the functions of renal 512Ag in vivo an isolated
kidney perfusion technique was used. The procedure of left
kidney perfusion has been described previously [11, 12]. Briefly,
the left kidney of a rat was exposed under ether anesthesia.
Polyethylene tubes were placed in the left renal artery and vein,
and proximal portions of the vessels were temporarily ligated. The
left kidney was perfused at the rate of 2 mI/mm using a peristaltic
pump. Modified Tyrode buffer saturated with 95% oxygen and 5%
carbon dioxide was used as a vehicle. All the perfusate was
discarded through a tube placed in the renal vein. After kidney
perfusion, tubes were removed and the holes in the artery and
vein were repaired by microsurgery. Blood circulation of the left
kidney was re-established by releasing the ligature. The average
time required for perfusion procedure was about 10 minutes. To
see the localization of mouse IgG after kidney perfusion, rats were
perfused with 0.3mg of F(ab')2 fragments of 512 or H38 in 10 ml
of buffer according to the procedure described above. Rats were
sacrificed 15 minutes after recirculation of the kidney, and
localization of mouse IgG and rat C3 in the kidney was examined
by IF.
Experimental protocol
Rats were divided into five groups. Each group of rats were
treated as described below.
Group I. The left kidney was perfused with 0.3 mg of F(ab')2
fragments of mAb 512. Five minutes after re-establishment of
renal blood flow, 0.9 ml of rabbit anti-rat GBM antisera were
injected from the tail vein.
Group II. The left kidney was perfused with F(ab')2 fragments
of irrelevant mAb H38 and the same amount of anti-GBM
antisera was injected.
Group III. The left kidney was perfused with 0.3 mg of F(ab')2
fragments of 512 and normal rabbit serum instead of anti-GBM
antisera was intravenously injected. Rats of Groups I, II and III
were sacrificed at I (Day 1), 5 (Day 5) and 14 (Day 14) days after
perfusion/injection.
Group IV. Rats were intravenously injected with 25 units of
cobra venom factor 12 hours before perfusion. Serum comple-
ment hemolytic activity (CH5O) was undetectable for at least three
days by this treatment. Rats were then treated in the same way as
Group I rats. Rats were sacrificed at Days 1 and 5.
Group V. To see the effect of proteinuria on the accessibility of
intravenously injected anti-GBM antibodies to TBM, five rats
Table 1. Protocol of the experiments
Group Pretreatment Perfusion iv. Day I Day 5 Day 14
I no 512 RbAGBM 5 5 4
II no H38 RbAGBM 4 5 4
III no 512 NRbS 4 5 4
IV CVF 512 RbAGBM 4 5 0
V PAN no persuion RbAGBM 3 0 0
The number in the column indicates the number of rats examined at
individual time point. Abbreviations are: CVF, cobra venom factor; PAN,
puromycin of aminonucteoside; RbAGBM, rabbit antiseum against rat
GBM; NRbS, normal rabbit serum.
received intraperitoneal injection of 15 mg of puromycin amino-
nucleoside (PAN). Seven days later, three rats started to reveal
mild proteinuria ranging from 8 to 15 mgIl6 hr. These rats were
then intravenously injected with 0.9 ml of anti-GBM serum. Rats
were sacrificed at 24 hours after antibody injection, and left
kidneys were examined by IF for the deposition of antibodies
along TBM. The protocol is shown in Table 1.
Histology and immunohistology
At the time of sacrifice, a piece of kidney tissue was fixed in
methacain fixative and embedded in paraffin for light microscopy.
Two micrometer thick sections were stained with periodic acid-
Schiff reagent. For IF study, fragments of kidney tissue were
snap-frozen in liquid nitrogen and kept at —70°C until use. Two
micrometer thick sections were cut by a cryostat and fixed in
acetone for 10 minutes at room temperature. Sections were
washed in PBS and then incubated with specific antibodies
conjugated with fluorescein for 15 minutes at room temperature.
For the detection of mouse IgG, fluorescein-labeled rabbit anti-
mouse IgG antibodies (Cappel Laboratories, Westchester, PA,
USA) absorbed with normal rat serum were used. Fluoreceinated
goat antibodies against rabbit IgG (Cappel) absorbed with normal
rat and mouse sera were used to detect rabbit IgG in the sections.
Fluorescein-labeled rabbit anti-rat C3 antibodies were used for
the detection of rat C3. To assess the leukocyte infiltration in the
kidney, fluorescein-labeled monoclonal antibody (OXI) against
rat leukocyte common antigen (LCA) purchased from Dainippon
Pharmaceutical Company (Suita, Japan) was used. For the assess-
ment of damaged tubules [13], kidney sections were incubated
first with monoclonal anti-vimentin antibody (BioMakor, Reho-
vot, Israel) and then with fluorescein-conjugated rabbit anti-
mouse IgG. After the final wash in PBS, all the sections were
mounted in media containing p-phenylenediamine [14] and were
observed through an Olympus epifluorescence microscopy (To-
kyo, Japan).
Quantitation of data
For quantitation of data, specimens were examined by two
observers using a blinded study method. The number of nuclei in
the equatorially cut, glomerular cross section was counted.
Twenty glomeruli were examined and the average number was
used as total glomerular cell count in each rat. The number of
LCA-positive cells in the glomerular cross section was counted
similarly, and the average number of 20 glomeruli was used as an
index of glomerular leukocyte infiltration. Data in the cortical
tubulointerstitial tissue were obtained by 20 areas randomly
observed under microscope at high magnification (X400). For the
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Fig. 1. Immunofluorescence micrographs showing the binding of mAb 512 and rat C3 15 minutes after perfusion and recirculation in Group III rats. 512
bound weakly in the mesangial area and along glomerular (A) and peritubular capillaries (B). Binding of 512 was also seen in the basal membrane of
the proximal tubules (A, B). Deposition of rat C3 was weakly seen in the mesangial area (C). Strong deposition of rat C3 was seen in the peritubular
capillaries (D). (A—D x400)
Fig. 2. Immunofluorescence micrographs showing the binding of rabbit IgG (anti-GBM antibodies) in the kidneys one day after perf usion and recirculation.
Rabbit IgG bound to GBM strongly in Groups 1(A), 11(B), IV (C) and V (D). Binding of rabbit IgO to TBM was observed only in Group I rats (A).
(A—D x100)
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Table 2. Summaiy of immunofluorescence staining
Group
Days after
injection
GBM TBM (cortex)a Vessel wall Peritubular capillaries
Rabbit IgG Rat C3 Rabbit IgG Rat C3 Rabbit IgG Rat C3 Rabbit IgG Rat C3
I 1 ++++ ++ +++ + +I++ —1+ ++ +
I 5 ++++ + +++ + +I++ —1+ ++ +
I 14 +++ + ++
—1+ — — — —
II 1 ++++ ++
—1+ — — — -.-
II 5 ++++ +
—1+ — — — — —
II 14 +++ + — — — — — —
III 1 — — — + — — —
—1+
III 5 — — + — — — —1+
III 14 - — — — — — — —
IV 1 ++++ — —1+ — — — — —
IV 5 ++++
—1+ —1+ — — — — —
V 1 ++++ ++ —1+ — — — — —
Staining intensity was graded from (—) to (+ ++ +). For the evaluation of binding of rabbit IgG and rat C3 to the cortical TBMa, following criteria
were used: (—), deposition of rabbit IgG to less than 5% of TBM; (+), 5—30% of TBM; (++), 30—70% of TBM; (+++), more than 70% of TBM. In
case of C3 deposition along TBW, circumferential deposition of C3 was defined as positive in each tubule because interrupted or discrete deposition
of C3 is often observed in the TBM of normal rats.
evaluation of leukocyte infiltration, the average number of LCA-
positive cells in a high magnification field was used in each rat. For
the evaluation of proximal tubule damage, the extent of cytoplas-
mic staining of vimentin was graded from 0 to 3. In this case, each
specimen was observed at a moderate magnification (x200). Ten
areas were randomly observed and each area was graded accord-
ing to the following definition: grade 0, no cytoplasmic staining;
grade 1, cytoplasmic staining of proximal tubules in less than of
tubules; grade 2, positive staining between 1/3 to 2/3 of tubules;
grade 3, positive staining in more than 2/3 of tubules. The average
grade of 10 different areas was used as a representative grade of
each rat.
Urinaiy protein measurements
Rats were housed in the metabolic cages overnight (about 16
hr) every other day after perfusion. Urine samples were collected
and protein concentration was measured by a pyrogallol red
method {15j.
Statistics
The data were analyzed by one factor ANOVA. When a
significant difference was indicated, statistical analysis was further
performed by Scheffe's F-test to evaluate the statistical difference
between any pair of groups. In case of tubular vimentin staining,
only Group I and III rats showed positive staining at Day 5; no rat
in the other groups (II and IV) showed positive staining. Thus, the
statistical difference between Groups I and III was analyzed using
the Mann-Whitney U-test. The statistical difference between two
groups was determined when the P value was less than 0.05 (5%).
Results
Localization of 512 and C3 deposition after perfusion with 512
Binding of mouse IgG was observed in glomeruli, peritubular
capillaries, and basal membranes of proximal tubules 15 minutes
after perfusion of the kidney with 512 and recirculation (Fig. 1 A,
B). There was weak binding of C3 in the glomerulus (Fig. 1C), and
strong C3 deposition in the peritubular capillaries (Fig. 1D). In
rats perfused with control mAb 1138, significant binding of mouse
IgG or C3 was not observed 15 minutes after perfusion.
Fig. 3. Immunofluorescence micrographs showing the binding of rabbit IgG
(anti-GBM antibodies) in the kidneys five days after perfusion and recircu- IF staining for mouse IgG, rabbit IgG, rat IgG and rat C3
lation. Rabbit IgG bound to GBM strongly in rats of Group 1(A) 11(B)
and IV (C). Strong binding of rabbit IgG to TBM was seen only in Group Mouse IgG. Binding of mouse IgG was observed weakly in the
I rats (A). (A—D >< 100) glomerulus and in the peritubular capillaries in Group I, III and
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Fig. 4. Immunofluorescence micrographs showing the deposition of rat C3 in the kidneys Jive days after perJhsion and recirculation. C3 deposition along
GBM was seen in Groups 1(A) and 11(B) but not Group III (C) nor IV (D). Circumferential deposition of rat C3 along TBM was observed focally in
the rat kidneys of Group I (A) and III (C). In rats of Group I, deposition of rat C3 was also observed in the perivascular tissue (A). (A—D X200)
IV rats at Day 1. Mouse IgG was moderately seen in the proximal
tubules and in the vascular bandies in these rats. At Day 5
onwards, mouse IgG was not detectable in the kidneys of these
groups. Mouse IgG was not detectable in the kidneys of Group II
rats throughout the experiments.
Rabbit IgG. Binding of rabbit IgG was strongly observed along
GBM in Groups I, II, and IV both at Days 1 and 5 (Table 2). In
Group I rats, binding of rabbit IgG was also strongly observed
along TBM of proximal tubules both at Day 1 and Day 5 (Figs. 2
and 3). In addition, binding was also seen weakly to moderately in
the vessel wails and peritubular capillaries. In contrast, there was
practically no binding of rabbit IgG to TBM in other groups of
rats throughout the experiments. In rats made slightly proteinuric
by puromycin aminonucleoside, binding of rabbit IgG to TBM was
seldom observed at Day 1, while there was strong binding to GBM
(Fig. 2).
Rat IgG. Binding of rat IgG was not observed at Day 1 in the
kidneys of all rats. At Day 5, there was weak binding of rat IgG to
GBM of Groups I, II and IV. In rats of Group I, there was also
weak binding of rat IgG to occasional TBM. At Day 14, linear
deposition of rat IgG was clearly seen along GBM of Group I and
II rats. Binding of rat IgG to TBM was not observed in rats of any
group at this stage.
Rat C3. Deposition of rat C3 to GBM was weakly seen in Group
I, II and V rats at Day 1, and in rats of Groups I and II at Days
5 and 14 (Table 2). There was no C3 deposition to GBM in Group
III and IV rats (Fig. 4). Circumferential binding of rat C3 along
TBM was seen in some tubules of Group I and III rats at Days I
and 5 (Fig. 4). Significant C3 binding to TBM was seldom seen at
Day 14 in these rats. Peritubular capillaries were positive for rat
C3 in Group I rats at Days 1 and 5. In Group II, IV and V rats,
abnormal binding of C3 was not seen in TBM and peritubular
capillaries. These results showed that perfusion of the kidney with
512 resulted in the binding of C3 along TBM and in peritubular
capillaries in concomitance with the increased binding of anti-
GBM antibodies along TBM.
Glomerular pathology
Rabbit anti-rat GBM antibodies used in the present work can
induce only mild glomerular pathology. Glomeruli of Group II
rats (perfusion of the left kidney with an irrelevant mAb H38
followed by intravenous injection of anti-GBM antibodies)
showed practically no glomerular pathology during the heterolo-
gous phase (--Day 5; Fig. 5A). At Day 14 there was a mild
increase of glomerular cellularity and leukocyte infiltration in this
group. Pretreatment of the left kidney with 512 (Group I rats)
induced a significant increase of total glomerular cells (Fig. 5A)
and leukocyte infiltration at Days 5 and 14 (Fig. 5B). 512 alone did
not induce any significant change in the glomerulus (Group III;
Fig. 5). Rats pretreated with CVF showed glomerular injury at
Day 5 comparable to Group I rats (Fig. 5). At Day 14 when an
autologous response was clearly observed, the overall glomeular
pathology was mild and crescent formation was not seen in any
rat. Among three groups (Groups I, II and III), rats of Group I
showed most prominent changes, that is, an increase of total
glomerular cells and infiltrated leukocytes. Glomeruli from rats of
Group II showed significantly milder alteration than Group I.
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Fig. 5. Glomerular cell number and leukocyte
infiltration in glomeruli. (A) Total glomerular
cell number shown by the number of nuclei per
equatorially cut, glomerular cross section. (B)
Glomerular leukocyte infiltration shown by the
number of LEA-positive cells per equatorially
cut, glomerular cross section. (*P < 0.05; P
< 0.01; NS, not significant.)
Tubulointerstitial pathology
In Group I and III rats there was degeneration of proximal
tubules and dilation of tubular lumen in the occasional area of
kidney cortex at Day 1. In the other groups the tubulointerstitial
tissue appeared normal. At Day 5, leukocyte infiltration and
tubular damage became prominent and were most severe in
Group I rats (Fig. 6A), although 512 itself could induce mild
tubulointerstitial injury at Day 5 (Fig. 6C) as reported before [16].
Anti-GBM antibodies alone did not induce any significant tubu-
lointerstitial pathology (Fig. 6B). Similarly, complement depletion
by CVF totally abrogated the combined effects of anti-GBM
antibodies and 512 (Fig. 6D). When the number of infiltrating
leukocytes was examined, the greatest increase was found in
Group I animals at Days 5 and 14 (Fig. 7A). In rats of Group III,
there was mild to moderate increase of leukocytes in the cortex at
Day 5, which became normal at Day 14. In Groups II and IV, the
number of leukocytes present in the cortex was within normal
range (Fig. 7A). When tubular damage was assessed by cytoplas-
mic expression of vimentin, proximal tubular cells in Group I rats
expressed vimentin most intensely at Day 5 (Fig. 7B). Rats of
Group III expressed vimentin less strongly, and rats of other
groups did not show any significant vimentin expression (Fig. 7B).
Thus, anti-GBM antibodies enhanced tubulointerstitial injury
induced by 512. At Day 14, tubulointerstitial changes in Group I
rats subsided significantly, although there was still mild cellular
infiltration. Group II and III rats showed normal tubulointerstitial
appearance at this stage.
Urinary protein excretion
The normal value in our laboratories for control female Wistar
rats was less than 3 mgIl6 hr. There was very mild proteinuria in
Group I (average 4.7 mg/16 hr, range 1.3 to 6.9 mg/16 hr) and III
rats (average 3.0 mg/16 hr, range 0.7 to 5.5 mg/16 hr) on Day Oil.
Proteinuria in these groups came to the upper limit of the normal
value (Group I, average 2.1, range 1.4 to 3.5 mg/16 hr; Group III,
average 3.0 mgil6 hr, range 1.1 to 6.8 mgIl6 hr) on Day 2/3, and
became normal on Day 4/5 onwards. In Group II and IV rats,
urinary protein excretion was less than 3 mgiI6 hr in all rats
throughout the experiments. Thus, rats of Group I and III showed
very mild proteinuria for the first several days of experiments.
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Fig. 6. Light microscopic micrographs of the kidneys five days after perfusion and recirculation. (A) Group I. (B) Group IL (C) Group III. (D) Group IV.
(A—D x200)
These data are shown in Figure 8. In three out of five rats
intraperitoneally injected with PAN, urinary protein started to
increase at the level of 8 to 15 mg/16 hr seven days after injection.
These rats were used as Group V rats.
Discussion
There are several hypotheses on the mechanisms of antibody
binding to TBM in human anti-GBM disease. First, anti-TBM
antibodies found in patients of anti—GBM disease contained
antibody (or antibodies) with different specificity against TBM
[17]. Different properties among anti-TBM antibodies might
determine the extent and intensity of antibody binding to TBM.
Second, even when anti-TBM antibodies with the same specificity
are involved, binding of antibodies to TBM was dependent on the
accessibility in vivo. Concerning the antibody binding to alveolar
basement membrane in anti-GBM disease, increased accessibility
of antibodies to the cross-reactive antigens due to increased
permeability of alveolar capillaries is considered to be important
[18—20]. Access of antibodies to TBM is achieved via two routes.
The first is direct diffusion of antibodies from the vasculature.
This might be achieved by the increased vascular permeability for
macromolecules. The second is the "back leak" of antibodies from
the tubular lumen, which could be possible when there is signifi-
cant proteinuria. Heterologous ant-rat GBM antibodies used in
the present work contained antibody fraction(s) which could react
with TBM because they could react with TBM when tested on the
normal rat kidney section. Anti-GBM antibodies are characteris-
tic in that they did not show any significant binding when
administered intravenously. Thus, the anti-GBM antibodies used
in this work were thought to be a type of tracer which could
potentially react with TBM but could not bind to TBM in vivo in
normal rats. Using these antibodies, the second hypothesis dis-
cussed above was examined in the present work.
Mouse Crry/p65 has dual functions mimicking human mem-
brane cofactor protein (MCP) and decay accelerating factor
(DAF) [211. In rats, 5I2Ag is the only membrane inhibitor at the
C3 convertase level known to date, and amino acid and cDNA
sequences of 5I2Ag were highly homologous to those of mouse
Crry/p65 [5]. Distribution of 5I2Ag in rats [22] was also similar to
that of Crry/p65 in mice [8]. In vivo administration of 512 induced
endotoxin shock-like symptoms [9] in rats, suggesting that 5I2Ag
plays crucial roles in maintaining the normal physiological condi-
tions against spontaneous and indiscriminate attack by autologous
complement. When function of 5I2Ag was suppressed in vivo by
Day-i Day-S Day-14
80
A
Leukocyte intiltration in cortex
100
60
40
20
0
** I
Hatanaka et al: Complement regulator in anti-GBM nephritis 1735
perfusing kidneys with a neutralizing mAb 512, mild and transient
tubulointerstitial injury pursued [16]. It is hypothesized from our
recent work that the vascular permeability is increased by com-
plement activation on the vascular endothelial cells after in vivo
administration of 512 [9]. The results obtained in the present study
revealed that intravenously administered anti-GBM antibodies
became highly accessible to TBM when function of renal 5I2Ag
was suppressed by mAb 512. The mechanism of binding of
anti-GBM antibodies to TBM in the present work was considered
as a direct diffusion of antibodies from the vasculature due to
increased vascular permeability rather than reabsorption by prox-
imal tubular cells of antibodies filtered from glomeruli. There are
two reasons to support this notion. First, in the early phase (15
mill after perfusion/recirculation), 512 bound to peritubular cap-
illaries and basal membrane of proximal tubules. At this stage,
there was strong deposition of complement C3 in the peritubular
capillaries but not in the tubules or tubular lumen. This observa-
tion showed that complement activation was first induced in the
peritubular capillaries. Second, there was strong binding of anti-
GBM antibodies to TBM at Day 1 in Group I rats. At this stage,
there was mild proteinuria in Groups I and III. To specify the
route by which antibodies reached the TBM, rats were first made
proteinuric by PAN, and then anti-GBM antibodies were injected
(Group V). At Day 1, there was no significant binding of
antibodies to TBM. This observation supported the hypothesis
that the mechanism of antibody binding to TBM in rats of Group
I was due to increased vascular permeability and diffusion of
macromolecules (including antibodies and complement compo-
nents) from the vasculatures.
mAb 512 itself could not induce any significant glomerular
injury. In rats of Group III (perfused with 512 and then injected
iv. with normal rabbit serum), mild C3 deposition in the glomeruli
was only transiently seen and rat C3 disappeared from glomeruli
at Day 1. Anti-GBM antibodies used in this study could not
induce glomerular pathology at Day 1 and Day 5 as seen in Group
II rats. The fact that glomerular injury was evident in Group I
suggested that pretreatment of kidney with mAb 512 worsened the
anti-GBM antibody-mediated glomerular injury. At at Day 5,
there was weak binding of rat IgG along the GBM in Groups I, II,
and IV, indicating that autologous phase (antibody response to
heterologous rabbit IgG) already started at this stage. The reason
why the glomerular injury in Group IV (complement depleted
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Fig. 8. Urinaiy protein excretion during overnight
(16 hr). (*P < 0.05; **p < 0.01; NS, not
significant.)
rats) was comparable to that of Group I at Day 5 could be
explained by the previously reported findings that the autologous
phase of nephrotoxic serum nephritis was independent of com-
plement [23, 241.
Thus, intravenously administered anti-GBM antibodies (which
can potentially bind to TBM) gain the increased accessibility to
TBM when the function of a membrane inhibitor of complement
(5I2Ag) is inhibited by F(ab')2 fragment of 512. The findings
obtained in the present work might have relevance to the under-
standing of the mechanisms of antibody-mediated tubulointersti-
tial injuries.
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